Cite
MLA Citation
Francesca Aroldi et al.. “421 Initial results of a phase 1 trial of RP2, a first in class, enhanced potency, anti-CTLA-4 antibody expressing, oncolytic HSV as single agent and combined with nivolumab in patients with solid tumors.” Journal for immunotherapy of cancer, vol. 8, n.d., pp. A256–A257. http://access.bl.uk/ark:/81055/vdc_100144710368.0x000008